project id: TCGA-PRAD; case submitter id: TCGA-KC-A7FD; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.7; rna integrity number: 9.3; age at index: 62; days to birth: -22745; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1951; age at diagnosis: 22745; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 270.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 157; initial weight: 130.0; sample id: 68503fa7-00ca-407b-ae7d-403e7466b809; sample submitter id: TCGA-KC-A7FD-01A; portion id: 9c06ce07-a548-40a1-92c5-0f98904be55e; portion submitter id: TCGA-KC-A7FD-01A-11; slide id: 3e36e5e1-1410-4eaa-a48e-2e30216a24c2; slide submitter id: TCGA-KC-A7FD-01A-01-TSA; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;